PALI
PALISADE BIO, INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 12 ▼ 2 insiders sell $10.3K at $1.75
- Jun 29 FDA: Palisade Bio Receives FDA Clearance of IND for PALI-2108 a…
- Jul 1 to Jul 9 ▲ 6 days of insider buys: $250.2K by 1 insider, avg $2.00
- Jul 7 ▼ 2 insiders sell $409.9K at $2.06
- Jul 23 Oppenheimer initiates
- Sep 22 ▲ Palisade Bio announced FDA clearance of its IND application for PALI…
- Sep 22 FDA: Palisade Bio Receives FDA Clearance of IND for PALI-2108 i…
- Oct 1 to Oct 2 ▲ 2 days of insider buys: $28.8K by 1 insider, avg $1.44
- Oct 9 Raymond James initiates
Signal stack
Where each data set points today.
- InsidersMIXED
2 insiders bought $279.0K at an average $1.92. 2 insiders sold $420.2K. Price is 46% below their cost.
- InstitutionsBULLISH
Q3 2026: 16 added (0 new), 9 trimmed or exited.
- AnalystsBULLISH
16 of 17 rate it Buy or better. Every target is above the price.
- EstimatesFLAT
Current-quarter EPS estimate −$0.061 → −$0.061 over 90 days. 2 up, 4 down in 30 days.
- Short sellersSTEADY
Short interest −7.7% to 29.29M shares. 7.8 days to cover, ≈16.8% of shares.
- TrendDOWNTREND
29% below its 50-day average. New closing low $1.03 on Nov 16.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | DOUBLED | $10.6M |
| LOS ANGELES CAPITAL MANAGEMENT LLC | DOUBLED | $2.9M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | $1.9M |
| VANGUARD FIDUCIARY TRUST CO | ADD | $1.5M |
| UBS Group AG | ADD | $1.5M |
| Aberdeen Group plc | NEAR_EXIT | $1.2M |
| Nuveen, LLC | TRIM | $708.3K |
| AMERICAN CENTURY COMPANIES INC | ADD | $277.9K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
17 analystsPrice is below the lowest target. Median implies +628%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 11, 2026 | Piper Sandler MAINTAIN | Overweight |
| Nov 11, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Oct 13, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Oct 9, 2026 | Raymond James INITIATE | Outperform |
| Sep 23, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Jul 23, 2026 | Oppenheimer INITIATE | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Capers Julien E. See Remarks Oct 19, 2026 | AWARD | 787,300 sh |
Jones Mitchell Lawrence See Remarks Oct 6, 2026 | EXERCISE | 2,620,850 sh |
Finley John David CEO CFO Oct 6, 2026 | EXERCISE | 3,059,800 sh |
Finley John David CEO CFO Oct 6, 2026 | TAX W/H | $2.1M |
Jones Mitchell Lawrence See Remarks Oct 6, 2026 | EXERCISE | 2,555,266 sh |
Finley John David CEO CFO Oct 6, 2026 | EXERCISE | 3,227,384 sh |
Jones Mitchell Lawrence See Remarks Oct 6, 2026 | EXERCISE | 65,584 sh |
Finley John David CEO CFO Oct 6, 2026 | EXERCISE | 167,584 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.06 | -$0.07–-$0.05 | +0.3% | $0.00 |
| Next Q | -$0.08 | -$0.08–-$0.08 | -20.0% | $0.00 |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | -$0.33 | -$0.41–-$0.29 | -16.7% | $0.00 |
Short side
FINRA· Oct 30, 2026SecBot reports
13 filings · 1 press release · 0 bullish · 0 bearish · 1 mixed · 12 neutral- NEUTRAL SC 13G/ANov 16, 2026
Ameriprise Financial, Inc. filed an amended Schedule 13G disclosing a passive 8.4% stake in Palisade Bio, Inc., holding 14,567,993 shares as of September 30, 2026. The stake is held through its subsidiary Columbia Management Investment Advisers, with the Seligman Healthcare Spectrum (Master) Fund…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 8-KNov 10, 2026
Palisade Bio reported Q3 2026 net loss of $14.6M ($0.07 per share), wider than the $2.9M loss a…
The key catalyst is the ASCENTRA-UC topline readout in Q4 2027, with ASCENTRA-CD enrollment initiation in Q1 2027 as a near-term milestone. Cash runway through both readouts reduces near-term…
- NEUTRAL SC 13G/ANov 9, 2026
Soleus Capital Master Fund, L.P. filed an amended Schedule 13G disclosing a 8.6% passive stake in…
Monitor for any future conversion to a Schedule 13D (activist filing) or further stake changes. The increase to 8.6% by a hedge fund manager could precede engagement, but the passive filing suggests…
- NEUTRAL SC 13GOct 30, 2026
Vanguard Capital Management LLC disclosed a 5.16% passive stake in Palisade Bio, Inc. via a new…
Monitor for any future amendments that show an increase above 5.16%, which could signal a more active stance, though Vanguard's passive filing makes that unlikely. No immediate catalyst from this…
All PALI filing & press-release reports (14)
- SC 13G/A reportNov 16, 2026
- 8-K reportNov 10, 2026
- SC 13G/A reportNov 9, 2026
- SC 13G reportOct 30, 2026
- INST-CLUSTER reportSep 22, 2026
- PRESS-RELEASE reportSep 22, 2026
- 8-K reportAug 10, 2026
- CLUSTER reportJul 10, 2026
- CLUSTER reportJul 8, 2026
- 8-K reportJun 11, 2026
- EFFECT reportMay 22, 2026
- S-3 reportMay 12, 2026
- DEFA14A reportApr 29, 2026
- 8-K reportApr 2, 2026